Cargando…

Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe

Next-generation sequencing (NGS) may enable more focused and highly personalized cancer treatment, with the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines now recommending NGS for daily clinical practice for several tumor types. However, NGS implementation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horgan, Denis, Curigliano, Giuseppe, Rieß, Olaf, Hofman, Paul, Büttner, Reinhard, Conte, Pierfranco, Cufer, Tanja, Gallagher, William M., Georges, Nadia, Kerr, Keith, Penault-Llorca, Frédérique, Mastris, Ken, Pinto, Carla, Van Meerbeeck, Jan, Munzone, Elisabetta, Thomas, Marlene, Ujupan, Sonia, Vainer, Gilad W., Velthaus, Janna-Lisa, André, Fabrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780351/ https://www.ncbi.nlm.nih.gov/pubmed/35055387 http://dx.doi.org/10.3390/jpm12010072

Ejemplares similares

Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine
por: Horgan, Denis, et al.
Publicado: (2021)

aHIF but not HIF-1α transcript is a poor prognostic marker in human breast cancer
por: Cayre, Anne, et al.
Publicado: (2003)

Implementing TMB measurement in clinical practice: considerations on assay requirements
por: Büttner, Reinhard, et al.
Publicado: (2019)

PROCURE European consensus on breast cancer multigene signatures in early breast cancer management
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Testing for ROS1 in non-small cell lung cancer: a review with recommendations
por: Bubendorf, Lukas, et al.
Publicado: (2016)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Health Literacy: Read All about It …
por: Horgan, Denis, et al.
Publicado: (2017)

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
por: Cayre, Anne, et al.
Publicado: (2007)

Testing algorithm for identification of patients with TRK fusion cancer
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin
por: Pujol, Pascal, et al.
Publicado: (2019)

Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer
por: El Guerrab, Abderrahim, et al.
Publicado: (2017)

P-gp expression in brown trout erythrocytes: evidence of a detoxification mechanism in fish erythrocytes
por: Valton, Emeline, et al.
Publicado: (2013)

Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen
por: Basu, Samar, et al.
Publicado: (2015)

Circulating proteins as predictive and prognostic biomarkers in breast cancer
por: Veyssière, Hugo, et al.
Publicado: (2022)

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib
por: Dufour, Robin, et al.
Publicado: (2015)

Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ
por: Beguinot, Marie, et al.
Publicado: (2018)

Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer
por: El Guerrab, Abderrahim, et al.
Publicado: (2011)

Mini-P-gp and P-gp Co-Expression in Brown Trout Erythrocytes: A Prospective Blood Biomarker of Aquatic Pollution
por: Valton, Emeline, et al.
Publicado: (2015)

Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2018)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

Interest and Limits of [(18)F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy
por: Jouberton, Elodie, et al.
Publicado: (2021)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
por: Collet, Laetitia, et al.
Publicado: (2022)

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
por: Thunnissen, Erik, et al.
Publicado: (2012)

Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers
por: Fkih M’hamed, Insaf, et al.
Publicado: (2015)

Being on active surveillance: the patient perspective
por: Mastris, Ken, et al.
Publicado: (2018)

Novel Proteome Extraction Method Illustrates a Conserved Immunological Signature of MSI-H Colorectal Tumors
por: Vainer, Elez D., et al.
Publicado: (2020)

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
por: van de Vijver, Marc, et al.
Publicado: (2007)

SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2018)

Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2017)

The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
por: Dubois, Clémence, et al.
Publicado: (2019)

Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto
por: Cardoso, Fatima, et al.
Publicado: (2021)

Chemical biology fluorescent tools for in vitro investigation of the multidrug resistant P-glycoprotein (P-gp) expression in tumor cells
por: Daumar, Pierre, et al.
Publicado: (2023)

Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications
por: Vainer, Gilad, et al.
Publicado: (2023)

The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer
por: Karsli-Ceppioglu, Seher, et al.
Publicado: (2017)

Refining patient selection for breast cancer immunotherapy: beyond PD-L1
por: Kossai, M., et al.
Publicado: (2021)

Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines
por: Dubois, Clémence, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_arvgn1n9n3ep7v1q42af0m35ag